Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

alicaforsen

 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Antisense OligonucleotidesGastrointestinal AgentsImmunosuppressive AgentsPhosphorothioate Oligonucleotides

Narrower (1)

ISIS 2302

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series
Background and aims The published data about the efficacy of the intercellular adhesion molecule-1 (ICAM-1) antisense… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2007
2007
A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
BACKGROUND & AIMS The aim of this study was to compare the safety and efficacy of alicaforsen, a first-generation antisense… Expand
Is this relevant?
2006
2006
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
BACKGROUND Alicaforsen is a phosphorothioate-modified antisense oligodeoxynucleotide designed to sequence-specifically reduce… Expand
Is this relevant?
2006
2006
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active…
BACKGROUND Alicaforsen is an antisense oligonucleotide inhibitor of intercellular adhesion molecule 1 protein expression with… Expand
Is this relevant?
2004
2004
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.
BACKGROUND Pouchitis is the major long-term complication of ileal pouch-anal anastomosis for ulcerative colitis. The incidence of… Expand
Is this relevant?
2004
2004
escalating dose study of alicaforsen enema in active ulcerative colitis
Objective: To evaluate the safety and efficacy of an enema formulation of alicaforsen, an antisense inhibitor of intercellular… Expand
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 1
Is this relevant?
2004
2004
A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
OBJECTIVE To evaluate the safety and efficacy of an enema formulation of alicaforsen, an antisense inhibitor of intercellular… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn…
BACKGROUND AND AIMS To evaluate the safety and efficacy of the intercellular adhesion molecule 1 (ICAM-1) antisense… Expand
Is this relevant?
2002
2002
Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
BACKGROUND AND AIMS To evaluate the safety, pharmacokinetics and clinical efficacy of the intercellular adhesion molecule-1… Expand
Is this relevant?
Review
2001
Review
2001
Alicaforsen. Isis Pharmaceuticals.
Alicaforsen (ISIS-2302) is an RNase H-dependent antisense inhibitor of the intercellular adhesion molecule ICAM-1 under… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE